Security key
61023L108
- Security type / class
- Equity / COM
- Total 13F shares
- 207,329
- Total 13F value
- $470,610
- Share change
- +3,373
- SEC-reported price per share
- $2.25
- Number of holders
- 9
- Value change
- +$9,868
- Number of buys
- 1
- Number of sells
- 4
Report period
Q2 2022
Institutions
9
Top holders
9
MNPR full security history
Ownership snapshot
Full 13F holder table
Monopar Therapeutics SEC filings
Monopar Therapeutics company facts
Monopar Therapeutics 13D/G history
Broader feeds
Ownership snapshot
Top reported holders of MNPR - MONOPAR THERAPEUTICS INC - COM (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
VANGUARD GROUP INC
Disclosed value leader
VANGUARD GROUP INC
Comparable rows
0/13
Latest evidence
31 Mar 2022
13F
3/4/5
Highest disclosed value: $255,000
13 rows are not safely comparable across share classes.
Showing 1-6 of 13 holder rows.
Quick read
VANGUARD GROUP INC has the largest disclosed position value at $255K.
0 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens VANGUARD GROUP INC's linked filing trail.
Disclosed position value
Top 5
VANGUARD GROUP INC
$255K
GEODE CAPITAL MANAGEMENT, LLC
$100K
Andrew Paul Mazar
$94.4K
NORTHERN TRUST CORP
$90K
BlackRock Finance, Inc.
$35K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
Company
|
—
denominator unverified
|
$255,000
99,879 shares
|
— | 31 Mar 2022 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
denominator unverified
|
$100,000
39,171 shares
|
— | 31 Mar 2022 |
| Andrew Paul Mazar |
3/4/5
Chief Scientific Officer, Director
|
—
mixed-class rows
|
$94,434
277,584 shares
mixed-class rows
|
— | 31 Mar 2022 |
| NORTHERN TRUST CORP |
13F
Company
|
—
denominator unverified
|
$90,000
35,207 shares
|
— | 31 Mar 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
—
denominator unverified
|
$35,000
13,717 shares
|
— | 31 Mar 2022 |
| IFP Advisors, Inc |
13F
Company
|
—
denominator unverified
|
$13,000
500 shares
|
— | 31 Mar 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
9
Shares
207,329
Rows available
9
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
10
Q2 2022 holders
9
Holder diff
-1
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 value | Q2 2022 value | Value change | Value Chg % |
|---|